Vyera and Martin Shkreli fail in bid to end Daraprim lawsuit

A federal judge in New York has ruled that Martin Shkreli and his company Vyera Pharmaceuticals must face an FTC lawsuit accusing them of scheming to maintain the company’s monopoly over antiparasitic drug Daraprim.


Get unlimited access to all Global Competition Review content